SML2293
NSC61610
≥98% (HPLC)
Synonym(s):
CID247228, N1,N4-Bis[3-(1H-benzimidazol-2-yl)phenyl]-1,4-benzenedicarboxamide, NCI 61610
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C34H24N6O2
CAS Number:
Molecular Weight:
548.59
UNSPSC Code:
12352200
NACRES:
NA.77
Assay
≥98% (HPLC)
form
powder
color
off-white to purple
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C(C1=CC=C(C=C1)C(NC2=CC=CC(C3=NC4=C(N3)C=CC=C4)=C2)=O)NC5=CC(C6=NC7=C(N6)C=CC=C7)=CC=C5
Biochem/physiol Actions
NSC61610 is an orally available and potent lanthionine synthetase C-like 2 (LANCL2) ligand that induces IL-10-mediated anti-inflammatory responses that ameliorate disease activity and decrease inflammatory lesions in the gut. Also NSC61610 modulates immune response to influenza A H1N1pdm virus infection in mice.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Adria Carbo et al.
Journal of medicinal chemistry, 59(22), 10113-10126 (2016-12-10)
Lanthionine synthetase C-like 2 (LANCL2), a novel therapeutic target for inflammatory and autoimmune diseases and diabetes, exerts anti-inflammatory and insulin-sensitizing effects. This study reports the first LANCL2-based therapeutics for inflammatory bowel disease (IBD). Analogues of 1 (ABA) and 2 (NSC61610)
Pinyi Lu et al.
PloS one, 7(4), e34643-e34643 (2012-04-18)
Lanthionine synthetase component C-like protein 2 (LANCL2) is a member of the eukaryotic lanthionine synthetase component C-Like protein family involved in signal transduction and insulin sensitization. Recently, LANCL2 is a target for the binding and signaling of abscisic acid (ABA)
Andrew Leber et al.
Frontiers in immunology, 8, 178-178 (2017-03-09)
Broad-based, host-targeted therapeutics have the potential to ameliorate viral infections without inducing antiviral resistance. We identified lanthionine synthetase C-like 2 (LANCL2) as a new therapeutic target for immunoinflammatory diseases. To examine the therapeutic efficacy of oral NSC61610 administration on influenza
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service